Cue Reactivity Model/Pharm. Intervention in Cannabis Use

提示反应模型/药物。

• 批准号: 6878831
• 负责人: LESLIE H Lundahl
• 金额: $ 21.87万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-27 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6878831
• 关键词: behavioral /social science research tag; blood pressure; cannabinoids; clinical research; craving; cues; drug abuse chemotherapy; drug addiction; heart rate; human subject; marijuana abuse; model design /development; psychological models; questionnaires

DESCRIPTION (provided by applicant): Marijuana is the most commonly used illegal drug in the United States, and more than 2 million Americans are abusing or dependent on the drug. Demand for treatment is increasing, and treatment outcome studies indicate high relapse rates that are comparable to those of other substance use disorders. Thus, there is a clear need for treatment options, particularly as adjuncts to standard behavioral strategies. The development of a medication to reduce use and/or prevent relapse recently has become a focus of research, most of which targets the alleviation of cannabis withdrawal symptoms. Given that craving is a phenomenon reported by the majority of individuals who abuse marijuana, and is thought to be related both to the perpetuation of abuse and to relapse, the attenuation of craving also should be a focus of putative medications. Currently there are no validated laboratory models to evaluate the efficacy of a pharmacologic compound to reduce marijuana craving. The current application proposes studies that are necessary to develop and test a marijuana cue reactivity paradigm that enables the successful induction and quantitative measurement of marijuana craving in a controlled laboratory setting. In this model, subjective and physiological responses both to marijuana-related cues (e.g., paraphernalia) and to drug unrelated (i.e., neutral) cues are compared in cannabis dependent individuals. Numerous laboratory studies show this paradigm elicits robust craving using cues associated with drugs of abuse including alcohol, cocaine, opiates, and nicotine. It has not been tested with marijuana cues, thus the specificity of marijuana cue-induced reactivity is not known. We propose to establish the specificity of the marijuana cue reactivity paradigm, and then to test the sensitivity of the model using a prototypic cannabinoid agonist, ?9-tetrahydrocannabinol (oral THC). If these preliminary and exploratory studies indicate that the cue reactivity paradigm is both specific and sensitive, it can then be used with confidence to examine whether pretreatment with certain compounds can attenuate craving and reactivity to marijuana-related cues. This paradigm will help identify the most promising medications prior to undertaking expensive and time-consuming clinical trials. It will also be useful in the testing of pharmacologic treatments in combination with evidence-based behavioral interventions that have the potential to lead to successful integrative treatment for cannabis use disorders.

描述（由申请人提供）：大麻是美国最常用的非法药物，超过200万美国人滥用或依赖这种药物。对治疗的需求正在增加，治疗结果研究表明，复发率很高，与其他药物使用障碍的复发率相当。因此，显然需要治疗方案，特别是作为标准行为策略的替代品。开发一种减少使用和/或预防复发的药物最近已成为研究的焦点，其中大部分针对减轻大麻戒断症状。鉴于渴望是大多数滥用大麻的人报告的一种现象，并且被认为与滥用的持续和复发有关，渴望的减弱也应该是公认药物的重点。目前，还没有经过验证的实验室模型来评估药物化合物减少大麻渴望的功效。本申请提出了开发和测试大麻线索反应性范例所必需的研究，所述大麻线索反应性范例能够在受控的实验室环境中成功诱导和定量测量大麻渴望。在这个模型中，对大麻相关线索的主观和生理反应（例如，用具）和与药物无关的（即，中性）线索进行比较。大量的实验室研究表明，这种模式利用与滥用药物（包括酒精、可卡因、阿片类药物和尼古丁）相关的线索来激发强烈的渴望。它还没有用大麻线索进行测试，因此大麻线索诱导反应的特异性尚不清楚。我们建议建立大麻线索反应性范例的特异性，然后使用原型大麻素激动剂，测试模型的敏感性？9-四氢大麻酚（口服THC）。如果这些初步和探索性的研究表明，线索反应范式是既具体又敏感，那么它可以被用来检查是否预处理与某些化合物可以减弱渴望和反应大麻相关的线索。这种模式将有助于在进行昂贵和耗时的临床试验之前确定最有前途的药物。它也将有助于药物治疗与循证行为干预相结合的测试，这些干预有可能导致大麻使用障碍的成功综合治疗。